Dapagliflozin reduces loop diuretic requirement over time in patients with heart failure with mildly reduced or preserved ejection fraction in the DELIVER Trial

Back

HFA Premium Access

Dapagliflozin reduces loop diuretic requirement over time in patients with heart failure with mildly reduced or preserved ejection fraction in the DELIVER Trial

Session: Pharmacotherapy

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Doctor S. Chatur (Boston, US)

Event: Heart Failure 2023

Congress Presentation

About the speaker

Doctor Safia Chatur

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)

0 follower

6 more presentations in this session

Real-world use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry

Speaker: Doctor D. Stolfo (Trieste, IT)

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial.

Speaker: Doctor J. Tromp (Singapore, SG)

Safety of continuing mineralocorticoid receptor antagonists treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from swedish heart failure registry

Speaker: Doctor F. Guidetti (Stockholm, SE)

Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure

Speaker: Ms I. Beldhuis (Groningen, NL)

Impact of lower systolic blood pressure on efficacy and safety of sacubitri/valsartan compared to ramipril in patients with acute myocardial infarction: insights from PARADISE-MI trial

Speaker: Doctor M. Senni (Bergamo, IT)

Access the full session

Pharmacotherapy

Speakers: Doctor S. Chatur, Doctor D. Stolfo, Doctor J. Tromp, Doctor F. Guidetti, Ms I. Beldhuis...

Access

Video

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

Dapagliflozin reduces loop diuretic requirement over time in patients with heart failure with mildly reduced or preserved ejection fraction in the DELIVER Trial

About the speaker

Doctor Safia Chatur

6 more presentations in this session

Real-world use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial.

Safety of continuing mineralocorticoid receptor antagonists treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from swedish heart failure registry

Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure

Impact of lower systolic blood pressure on efficacy and safety of sacubitri/valsartan compared to ramipril in patients with acute myocardial infarction: insights from PARADISE-MI trial

Access the full session

Pharmacotherapy

About the event

Heart Failure 2023

ESC 365 is supported by